Chr. Hansen reaches major milestone in innovation pipeline

Date 05.15.2018 | Category: News
| Comments:

Chr hansen trial IDM May18

Chr. Hansen completed a clinical trial1 using a carefully selected probiotic strain. Reaching both the primary and secondary end points of the trial, the results show a robust protective effect against gastrointestinal (GI) side effects caused by acetylsalicyclic acid (ASA).


Says Johan van Hylckama Vlieg, Vice President of Microbiome & Human Health Innovation: “The clinical trial identified that participants taking the probiotic experienced a significant defence against GI damage caused by a widely used household painkiller compared to those who took the placebo. This indicates a clear protective effect from the strain – both in terms of the reduction of intestinal damage and the number of ulcers caused.”


The clinical trial used capsule endoscopy to reveal GI damage. It’s one of the first times that this advanced technology is used in a probiotic intervention trial.


Common GI side effects

The household painkiller is an NSAID (non-steroidal anti-inflammatory drugs), which are some of the most widely used pharmaceuticals in the world. More than 50 million adults in the US take such drugs regularly. Chronic, low-dose use of the NSAID ASA is recommended for its cardiovascular-protecting properties and is today prescribed to 80% of those with an elevated cardiovascular risk profile in the US.


But the regular use of NSAIDs can have side effects. ASA has emerged as one of the most prominent causes of ulcer bleeding in developed countries over the last two decades, underscoring a clear, unmet need to protect the gastrointestinal against damage caused by long-term and chronic NSAID therapy.


Pioneering science

The clinical trial is a key milestone in Chr. Hansen’s probiotic innovation program. One of the focus areas of the innovation program is to prove the potential of probiotic strains to protect against intestinal damage and develop these into proprietary products.


Concludes van Hylckama Vlieg: “With this clinical data, we are breaking ground into a new field. As part of our Nature’s no. 1 strategy, we work to unleash the potential of probiotics as a safe and effective solution into new health areas. To do this, we focus on careful strain selection, high quality clinical trial design and professional execution. With this particular strain, we have reached a key milestone. We are now continuing to invest in this concept to further investigate the potential of the strain. Our goal is to make it available to the many millions who need to take ASA regularly to support their long-term health.” For more visit


Source: Chr Hansen
Author: COX
Load more news » Loading news